Interleukin-21: Basic biology and implications for cancer and autoimmunity

Annual Review of Immunology

Volumn 26, Issue , 2008, Pages 57-79

  Spolski, Rosanne ^a   Leonard, Warren J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Adaptive immunity; Antitumor; Blimp 1; Cytokine; Innate immunity; Plasma cell differentiation; Stat3

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ALPHA INTERFERON; BCG VACCINE; CD40 ANTIGEN; HERMES ANTIGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 21 RECEPTOR BLOCKING AGENT; INTERLEUKIN 23; INTERLEUKIN 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DR5; PROTEIN ROQUIN; RECEPTOR BLOCKING AGENT; REGULATOR PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR NFAT;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALITIS; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CALCIUM SIGNALING; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CELL TRANSFER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DENDRITIC CELL; DIABETES MELLITUS; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; FIBROSARCOMA; GENE LOCUS; GENE MUTATION; GENETIC CODE; GENETIC TRANSCRIPTION; HELPER CELL; HUMAN; IDD3 GENE; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; LYMPHOID CELL; MELANOMA; MONOTHERAPY; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUROTOXICITY; NONHUMAN; PANCREAS CARCINOMA; PATHOGENESIS; PLASMA CELL; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATOR GENE; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL; TH2 CELL; THYMOMA; UNSPECIFIED SIDE EFFECT;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DENDRITIC CELLS; HUMANS; INTERLEUKINS; LYMPHOCYTES; NEOPLASMS;

EID: 42649134105     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.26.021607.090316     Document Type: Review

References (93)

1. Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, et al. 1993. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73:147-57
2. Leonard WJ. 2001. Cytokines and immunodeficiency diseases. Nat. Rev. Immunol. 1:200-8
3. Leonard WJ, Spolski R. 2005. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 5:688-98
4. Ozaki K, Kikly K, Michalovich D, Young PR, Leonard WJ. 2000. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc. Natl. Acad. Sci. USA 97:11439-44
5. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, et al. 2000. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408:57-63
6. Habib T, Senadheera S, Weinberg K, Kaushansky K. 2002. The common γ chain (γc) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 41:8725-31
7. Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, et al. 2001. Cutting edge: the common γ-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167:1-5
8. Jin H, Carrio R, Yu A, Malek TR. 2004. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J. Immunol. 173:657-65
9. Bondensgaard K, Breinholt J, Madsen D, Omkvist DH, Kang L, et al. 2007. The existence of multiple conformers of interleukin-21 directs engineering of a superpotent analogue. J. Biol. Chem. 282:23326-36
10. Konforte D, Paige CJ. 2006. Identification of cellular intermediates and molecular pathways induced by IL-21 in human B cells. J. Immunol. 177:8381-92
11. Zeng R, Spolski R, Casas E, Zhu W, Levy DE, Leonard WJ. 2007. The molecular basis of IL-21-mediated proliferation. Blood 109:4135-42
12. Deleted in proof
13. Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, et al. 2007. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J. Immunol. 178:2827-34
14. Kim HP, Korn LL, Gamero AM, Leonard WJ. 2005. Calcium-dependent activation of interleukin-21 gene expression in T cells. J. Biol. Chem. 280:25291-97
15. Mehta DS, Wurster AL, Weinmann AS, Grusby MJ. 2005. NFATc2 and T-bet contribute to T-helper-cell-subset-specific regulation of IL-21 expression. Proc. Natl. Acad. Sci. USA 102:2016-21
16. Harada M, Magara-Koyanagi K, Watarai H, Nagata Y, Ishii Y, et al. 2006. IL-21-induced Aε cell apoptosis mediated by natural killer T cells suppresses IgE responses. J. Exp. Med. 203:2929-37
17. Brandt K, Bulfone-Paus S, Foster DC, Ruckert R. 2003. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 102:4090-98
18. Distler JH, Jungel A, Kowal-Bielecka O, Michel BA, Gay RE, et al. 2005. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum. 52:856-64
19. Caruso R, Fina D, Peluso I, Fantini MC, Tosti C, et al. 2007. IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J. Immunol. 178:5957-65
20. Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, et al. 2002. A critical role for IL-21 in regulating immunoglobulin production. Science 298:1630-34
21. Ozaki K, Hishiya A, Hatanaka K, Nakajima H, Wang G, et al. 2006. Overexpression of interleukin 21 induces expansion of hematopoietic progenitor cells. Int. J. Hematol. 84:224-30
22. Wu Z, Kim HP, Xue HH, Liu H, Zhao K, Leonard WJ. 2005. Interleukin-21 receptor gene induction in human T cells is mediated by T-cell receptor-induced Sp1 activity. Mol. Cell Biol. 25:9741-52
23. Jin H, Malek TR. 2006. Redundant and unique regulation of activated mouse B lymphocytes by IL-4 and IL-21. J. Leukoc. Biol. 80:1416-23
24. Good KL, Bryant VL, Tangye SG. 2006. Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21. J. Immunol. 177:5236-47
25. Brenne AT, Baa de Ro T, Waage A, Sundan A, Borset M, Hjorth-Hansen H. 2002. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 99:3756-62
26. Suto A, Nakajima H, Hirose K, Suzuki K, Kagami S, et al. 2002. Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line Cε transcription of IL-4-stimulated B cells. Blood 100:4565-73
27. Wood N, Bourque K, Donaldson DD, Collins M, Vercelli D, et al. 2004. IL-21 effects on human IgE production in response to IL-4 or IL-13. Cell Immunol. 231:133-45
28. + severe combined immunodeficiency. Nat. Genet. 20:394-97
29. Mehta DS, Wurster AL, Whitters MJ, Young DA, Collins M, Grusby MJ. 2003. IL-21 induces the apoptosis of resting and activated primary B cells. J. Immunol. 170:4111-18
30. Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, et al. 2004. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol. 173:5361-71
31. Tsuruoka N, Arima M, Arguni E, Saito T, Kitayama D, et al. 2007. Bc16 is required for the IL-4-mediated rescue of the B cells from apoptosis induced by IL-21. Immunol. Lett. 110:145-51
32. Calame KL, Lin KI, Tunyaplin C. 2003. Regulatory mechanisms that determine the development and function of plasma cells. Annu. Rev. Immunol. 21:205-30
33. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, et al. 2002. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17:51-62
34. Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, et al. 2005. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J. Immunol. 175:7867-79
35. Pene J, Gauchat JF, Lecart S, Drouet E, Guglielmi P, et al. 2004. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J. Immunol. 172:5154-57
36. Ettinger R, Sims GP, Robbins R, Withers D, Fischer RT, et al. 2007. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J. Immunol. 178:2872-82
37. Ng LG, Mackay CR, Mackay F. 2005. The BAFF/APRIL system: life beyond B lymphocytes. Mol. Immunol. 42:763-72
38. Weaver CT, Hatton RD, Mangan PR, Harrington LE. 2007. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25:821-52
39. Wurster AL, Rodgers VL, Satoskar AR, Whitters MJ, Young DA, et al. 2002. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon γ-producing Th1 cells. J. Exp. Med. 196:969-77
40. Chtanova T, Tangye SG, Newton R, Frank N, Hodge MR, et al. 2004. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J. Immunol. 173:68-78
41. H17 cells. Nature 448:484-87
42. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, et al. 2007. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448:480-83
43. H-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8:967-74
44. Suto A, Wurster AL, Reiner SL, Grusby MJ. 2006. IL-21 inhibits IFN-γ production in developing Th1 cells through the repression of Eomesodermin expression. J. Immunol. 177:3721-27
45. Strengell M, Sareneva T, Foster D, Julkunen I, Matikainen S. 2002. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J. Immunol. 169:3600-5
46. Pesce J, Kaviratne M, Ramalingam TR, Thompson RW, Urban JF Jr, et al. 2006. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J. Clin. Invest. 116:2044-55
47. Frohlich A, Marsland BJ, Sonderegger I, Kurrer M, Hodge MR, et al. 2007. IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. Blood 109:2023-31
48. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6:1123-32
49. Park H, Li Z, Yang XO, Chang SH, Nurieva R, et al. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6:1133-41
50. Li MO, Sanjabi S, Flavell RA. 2 006. Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25:455-71
51. H17 lineage. Nature 441:231-34
52. H17 and regulatory T cells. Nature 441:235-38
53. Kastelein RA, Hunter CA, Cua DJ. 2007. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25:221-42
54. H-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8:345-50
55. + T helper cells. Cell 126:1121-33
56. + T cell expansion and function. J. Exp. Med. 201:139-48
57. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. 2000. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat. Immunol. 1:426-32
58. + T cells in vivo by IL-15. Immunity 8:591-99
59. + T cells. J. Immunol. 175:755-62
60. Li Y, Bleakley M, Yee C. 2005. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J. Immunol. 175:2261-69
61. White L, Krishnan S, Strbo N, Liu H, Kolber MA, et al. 2007. Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV). Blood 109:3873-80
62. Cao X, Shores EW, Hu-Li J, An ver MR, Kelsall BL, et al. 1995. Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain. Immunity 2:223-38
63. DiSanto JP, Muller W, Guy-Grand D, Fischer A, Rajewsky K. 1995. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor γ chain. Proc. Natl. Acad. Sci. USA 92:377-81
64. Kasaian MT, Whitters MJ, Carter LL, Lowe LD, Jussif JM, et al. 2002. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16:559-69
65. Vosshenrich CA, Ranson T, Samson SI, Corcuff E, Colucci F, et al. 2005. Roles for common cytokine receptor γ-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J. Immunol. 174:1213-21
66. + cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur. J. Immunol. 33:3439-47
67. Toomey JA, Gays F, Foster D, Brooks CG. 2003. Cytokine requirements for the growth and development of mouse NK cells in vitro. J. Leukoc. Biol. 74:233-42
68. Brady J, Hayakawa Y, Smyth MJ, Nutt SL. 2004. IL-21 induces the functional maturation of murine NK cells. J. Immunol. 172:2048-58
69. Gays F, Martin K, Kenefeck R, Aust JG, Brooks CG. 2005. Multiple cytokines regulate the NK gene complex-encoded receptor repertoire of mature NK cells and T cells. J. Immunol. 175:2938-47
70. + T cells. J. Immunol. 176:1490-97
71. Godfrey DI, Kronenberg M. 2004. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114:1379-88
72. Wang G, Tschoi M, Spolski R, Lou Y, Ozaki K, et al. 2003. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 63:9016-22
73. Pelletier M, Bouchard A, Girard D. 2004. In vivo and in vitro roles of IL-21 in inflammation. J. Immunol. 173:7521-30
74. Ugai S, Shimozato O, Yu L, Wang YQ, Kawamura K, et al. 2003. Transduction of the IL-21 and IL-2 3 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther. 10:771-78
75. Di Carlo E, Comes A, Orengo AM, Rosso O, Meazza R, et al. 2004. IL-21 induces tumor rejection by specific CTL and IFN-γ-dependent CXC chemokines in syngeneic mice. J. Immunol. 172:1540-47
76. Takaki R, Hayakawa Y, Nelson A, Sivakumar PV, Hughes S, et al. 2005. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J. Immunol. 175:2167-73
77. + T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J. Immunol. 173:900-9
78. He H, Wisner P, Yang G, Hu HM, Haley D, et al. 2006. Combined IL-21 and low-dose IL-2 therapy induces antitumor immunity and long-term curative effects in a murine melanoma tumor model. J. Transl. Med. 4:24
79. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. 2007. Targeting death-inducing receptors in cancer therapy. Oncogene 26:3745-57
80. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, et al. 2004. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199:437-48
81. Roda JM, Parihar R, Lehman A, Mani A, Tridandapani S, Carson WE 3rd. 2006. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J. Immunol. 177:120-29
82. Smyth MJ, Hayakawa Y, Cretney E, Zerafa N, Sivakumar P, et al. 2006. IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy. J. Immunol. 176:6347-55
83. + T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 99:1259-66
84. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y. 2005. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med. 201:1973-85
85. Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, et al. 2007. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin. Cancer Res. 13:3630-36
86. Vinuesa CG, Cook MC, Angelucci C, Athanasopoulos V, Rui L, et al. 2005. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 435:452-58
87. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K. 2007. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J. Immunol. 178:3822-30
88. Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, et al. 2007. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 56:1152-63
89. Denny P, Lord CJ, Hill NJ, Goy JV, Levy ER, et al. 1997. Mapping of the IDDM locus Idd3 to a 0. 35-cM interval containing the interleukin-2 gene. Diabetes 46:695-700
90. King C, Ilic A, Koelsch K, Sarvetnick N. 2004. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117:265-77
91. Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, et al. 2007. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat. Genet. 39:329-37
92. Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, Shi FD. 2005. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J. Immunol. 174:2696-701
93. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, et al. 2006. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177:566-73